164 related articles for article (PubMed ID: 28087077)
1. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
2. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
3. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
4. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells.
Kiapour N; Wu B; Wang Y; Seyedsadr M; Kapoor S; Zhang X; Elzoheiry M; Kasimoglu E; Wan Y; Markovic-Plese S
J Immunol; 2022 Jul; 209(1):49-56. PubMed ID: 35750335
[TBL] [Abstract][Full Text] [Related]
6. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
7. Bifidobacterium animalis in combination with human origin of Lactobacillus plantarum ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance.
Salehipour Z; Haghmorad D; Sankian M; Rastin M; Nosratabadi R; Soltan Dallal MM; Tabasi N; Khazaee M; Nasiraii LR; Mahmoudi M
Biomed Pharmacother; 2017 Nov; 95():1535-1548. PubMed ID: 28946394
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
10. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling.
Wang Y; Telesford KM; Ochoa-Repáraz J; Haque-Begum S; Christy M; Kasper EJ; Wang L; Wu Y; Robson SC; Kasper DL; Kasper LH
Nat Commun; 2014 Jul; 5():4432. PubMed ID: 25043484
[TBL] [Abstract][Full Text] [Related]
11. Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis.
Wang H; Dong J; Shi P; Liu J; Zuo L; Li Y; Gong J; Gu L; Zhao J; Zhang L; Zhang W; Zhu W; Li N; Li J
Immunology; 2015 Feb; 144(2):254-62. PubMed ID: 25087772
[TBL] [Abstract][Full Text] [Related]
12. An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
Choi JH; Lee MJ; Jang M; Kim EJ; Shim I; Kim HJ; Lee S; Lee SW; Kim YO; Cho IH
PLoS One; 2015; 10(10):e0138592. PubMed ID: 26444423
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD48 Monoclonal Antibody Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of Pathogenic CD4+ T Cells.
McArdel SL; Brown DR; Sobel RA; Sharpe AH
J Immunol; 2016 Oct; 197(8):3038-3048. PubMed ID: 27581174
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
15. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
[TBL] [Abstract][Full Text] [Related]
16. A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation.
Wang Y; Begum-Haque S; Telesford KM; Ochoa-Repáraz J; Christy M; Kasper EJ; Kasper DL; Robson SC; Kasper LH
Gut Microbes; 2014 Jul; 5(4):552-61. PubMed ID: 25006655
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of experimental autoimmune encephalitis by novel peptides: involvement of T regulatory cells.
Shapira E; Brodsky B; Proscura E; Nyska A; Erlanger-Rosengarten A; Wormser U
J Autoimmun; 2010 Aug; 35(1):98-106. PubMed ID: 20434883
[TBL] [Abstract][Full Text] [Related]
18. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
19. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
